Towards a new definition of decompensated cirrhosis
- PMID: 34157322
- DOI: 10.1016/j.jhep.2021.06.018
Towards a new definition of decompensated cirrhosis
Erratum in
-
Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].J Hepatol. 2022 Mar;76(3):757. doi: 10.1016/j.jhep.2021.12.023. Epub 2022 Jan 5. J Hepatol. 2022. PMID: 34998627 No abstract available.
Abstract
There is a universal agreement that the occurrence of clinical complications, such as ascites, hepatic encephalopathy, gastrointestinal bleeding, and jaundice mark the transition from the compensated to the decompensated stage of cirrhosis. Decompensation is associated with a substantial worsening of patient prognosis and is therefore considered the most important stratification variable for the risk of death. However, this classification is an oversimplification, as it does not discriminate between the prognostic subgroups that characterise the course of decompensation, which depends on the type and number of decompensating events. A deeper insight into the clinical course of decompensated cirrhosis is provided by observational studies characterising acute decompensation (AD), which occurs mostly in patients who have already experienced decompensating events. Decompensation presents as AD in a portion of patients while in many others it presents as a slow development of ascites or mild grade 1 or 2 hepatic encephalopathy, or jaundice, not requiring hospitalisation. Thus, we propose that decompensation of cirrhosis occurs through 2 distinct pathways: a non-acute and an acute (which includes acute-on-chronic liver failure) pathway. Moreover, while non-acute decompensation is the most frequent pathway of the first decompensation, AD mostly represents further decompensation.
Keywords: acute decompensation; acute-on-chronic liver failure; ascites; bacterial infection; gastrointestinal bleeding; hepatic encephalopathy; jaundice; non acute decompensation; re-compensation.
Copyright © 2021. Published by Elsevier B.V.
Conflict of interest statement
Conflict of interest P.A.: 2016-2020 Biovie Advisory Board; 2018-2020 CSL Behring Speaker Invitation and Advisory Board; 2018-2020 Grifols Speaker invitation and Advisory Board; 2018-2020 Ferring Advisory Board. The other authors report no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources